Editorial: Might Astellas be the mystery bidder for Solvay's drug business?
This article was originally published in Scrip
Much of the speculation swirling around the possible sale of Solvay's pharmaceutical business has one thing in common: that, along with Nycomed, the other serious bidder is a Japanese firm. But which one is it?
You may also be interested in...
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.
Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.
Spreading China outbreak not a point of focus for companies or analysts in quarterly results briefings.